Tedizolid (also known as DA 715, TR 700, Torezolid) is a novel orally and intravenously administered intracellular antibacterial agent, which is a second generation oxazolidinone derivative that is 4-to-16-fold more potent against staphylococci and enterococci compared to linezolid.
In Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent.
Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
Comparative Efficacies of Tedizolid Phosphate, Vancomycin, and Daptomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis.
Comparative Efficacies of Tedizolid Phosphate, Linezolid, and Vancomycin in a Murine Model of Subcutaneous Catheter-Related Biofilm Infection Due to Methicillin-Susceptible and -Resistant Staphylococcus aureus.
Effects of Tedizolid Phosphate on Survival Outcomes and Suppression of Production of Staphylococcal Toxins in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia.
In vitro activity of tedizolid against the Mycobacterium abscessus complex.
In vitro activities of miltefosine and antibacterial agents from macrolide, oxazolidinone, and pleuromutilin classes against Pythium insidiosum and Pythium aphanidermatum.
Dissemination of Staphylococcus epidermidis ST22 With Stable, High-Level Resistance to Linezolid and Tedizolid in the Greek-Turkish Region (2008-2016).